BRÈVE

sur BioVersys AG

BioVersys Unveils Promising Phase 2a Results for Tuberculosis Treatment

BioVersys AG has announced promising results from its Phase 2a ENABLE study for tuberculosis treatments using AlpE. The study, conducted over 14 days, showed early bactericidal activity in all regimens tested in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

AlpE, a combination of alpibectir and ethionamide, was tested in conjunction with the RZE regimen, showing comparable efficacy to the standard HRZE treatment. These findings could pave the way for simpler treatments for isoniazid-resistant TB.

The trial, part of the UNITE4TB project, demonstrated that a higher 250 mg dose of ethionamide was more effective. AlpE was found to be generally well-tolerated during the trial, supporting further development towards potential new TB regimens.

The results were presented at the Union World Conference on Lung Health. BioVersys continues its collaboration with GSK and progresses with further trials, including a Phase 2b trial evaluating AlpE-RZE over two months.

R. E.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de BioVersys AG